December 10th, 2010 | Patna
Press Release Dissemination Centres: Ranchi, Jamshedpur, Dhanbad and Muzzafarpur
Cipla, the leading pharmaceutical company in association with Surya Chest Foundation today announced the launch of Progress to Prosper (P2P), a revolutionary asthma training and support initiative for the primary healthcare doctors across Bihar and Jharkhand. P2P has already been hugely successful in enhancing asthma care in Uttar Pradesh, Rajasthan, Haryana and Madhya Pradesh. The first workshop in the region will be extended to over 600 primary healthcare doctors in across cities like Patna, Gaya, Muzzafarpur, Samstipur, Bhagalpur, Purnia, Siwan and Motihari in Bihar; Ranchi, Jamshedpur and Dhanbad in Jharkhand.
P2P is the first and only program in India on diagnosis and management of asthma and with the support of doctors trained under P2P in the past 2 years, the best asthma treatment is now a reality even in small town India.
With over 30 million asthmatics in the country, India constitutes 10% of the world asthmatics which indicates that the asthma population in India is larger than the entire population of several countries. The scenario is worse as most in India are either unaware, undiagnosed or are sub-optimally treated for asthma. This is despite India having the latest, most effective and extremely affordable medicines to control asthma. In order to bridge this diagnosis-treatment gap and spread awareness, a holistic approach has been adopted in which P2P is proved to be the most important link.
P2P is a unique certificate program specifically designed in Hindi and it comprises of interactive lectures by eminent chest physicians and short easy-to-follow, user-friendly sessions. The doctors participating in the program also receive diagnostic tools and relevant patient educational materials which further supports them in their practice. Trained under P2P, the primary healthcare doctors are now able to extend the currently recommended therapy for asthma treatment to the masses. The most effective asthma treatment – inhalation therapy is available in India at a price as low as Rs 4 to Rs 6 per day. The diagnosed asthma patients can thereby benefit tremendously from the affordability and availability of these inhaled drugs to keep their asthma under control and lead a complete active life. Further, to ensure that patients take their treatment regularly, the primary healthcare doctors trained under P2P are able to provide demonstration of inhaler devices and counsel the patient and his family to remove the myths associated with asthma and inhalation therapy.
Addressing the press on the launch of P2P, Dr. Sandeep Bhattacharya, Physician & Associate Professor, C S M Medical University, Lucknow said, “For the first time a program has been designed specifically for primary physicians. The success of P2P in UP, Rajasthan, Haryana and MP encouraged Cipla and Surya Chest Foundation to extend this program in Bihar and Jharkhand as well. Today, a patient in Shoehar, Sheikhpur, Saran or in any other smaller location has access to the right asthma treatment as compared to a patient based in Mumbai or Delhi or even in developed countries with medication that is affordable to most people.
Commenting on the launch of P2P, Dr. Diwakar Tejaswi, Physician, K K Sharan Hospital said, “We are delighted about P2P being launched in Bihar and Jharkhand. We realize that doctors across Uttar Pradesh, Rajasthan, Haryana and MP have benefitted from P2P in terms of knowledge upgradation and winning patient trust”.
Speaking about the launch of P2P, Dr. Ravindra Kr Sinha, Chest Physician, Boring Road, Patna said, “Now, doctors from Bihar and Jharkhand would also be empowered to take up the responsibility to provide best asthma treatment to patients and provide relief to several suffering needlessly with the condition.”
Asthma is a chronic respiratory disorder of the lungs in which there is inflammation (swelling) of the airways in our lungs. Due to this inflammation, the airways are narrowed and the lung becomes vulnerable to various allergens which act as triggers for an asthma attack. Dust, cold, pollen, furry pets, and viruses, smoking and air pollutants, and even emotional agitation act as triggers for an asthma attack. When a person comes in contact with a trigger, the inflamed airways are irritated leading to tightening of the muscles and excess mucus production which further constricts the passages, thereby inhibiting normal breathing and this at times could even turn fatal.
The usual manifestations of asthma are repeated episodes of chest tightness, difficulty in breathing and cough. In children asthma often manifests through a single symptom like cough which is more severe at night or early in the morning and remains persistent despite intake of various cough syrups and medications. Asthma symptoms vary from person to person and it is important to watch them carefully for a correct diagnosis by the doctor.
Although asthma is not curable, it is possible to gain complete control over it and lead a normal active life. There are several therapies and forms of treatment for asthma available in the market. However, it has now been accepted globally that the best and safest way to take asthma medication is by inhalation as it reaches your lungs directly and starts acting immediately. But if you are on tablet or syrup the medication takes time to act as the medicine has to pass from the stomach to the blood and finally to the lungs. This could also result in several side effects. It is to be noted that in inhalation therapy, the dosage needed is up to 50 times lesser than syrups or tablets and far more effective. For more information on asthma, please log on to www.breathefree.com – an educational and informative website introduced by Cipla to help the people suffering from asthma across the world.
Cipla laid foundations for the Indian pharmaceutical industry back in 1935 with the vision to make India self-reliant in healthcare. Over the years Cipla has emerged as one of the most respected names not just in India but worldwide. Its state of the art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. With over 40 manufacturing units across the country, Cipla manufactures over 1200 products in 80 therapies.
With a turnover of over US $ 1 billion, Cipla serves doctors and patients in over 180 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices.